AlphaVax
Clinical-stage biopharmaceutical company developing self-replicating RNA (replicon) particle vaccine technology derived from attenuated alphaviruses. Focus areas include cancer immunotherapy, prophylactic infectious disease vaccines, biodefense vaccines, and veterinary vaccines via partner licensing. The company reports multiple completed Phase I/II trials, a portfolio of clinical and preclinical vaccine candidates, a scalable manufacturing process for virus-like replicon particles, and an extensive patent portfolio covering replicon technology.
Industries
Nr. of Employees
medium (51-250)
AlphaVax
Research Triangle Park, North Carolina, United States
Products
CEA-targeting replicon vaccine (colon/gastrointestinal cancer)
Replicon particle vaccine expressing carcinoembryonic antigen (CEA) evaluated in Phase I/II trials to elicit CEA-specific T cell and antibody responses and reduce regulatory T cell frequency.
HER2-targeting replicon vaccine (breast cancer)
Replicon particle vaccine expressing HER2 antigen tested in patients with HER2-expressing tumors to induce HER2-specific memory CD8 T cells and systemic immune responses.
PSMA-targeting replicon vaccine (prostate cancer)
Replicon particle vaccine encoding prostate-specific membrane antigen (PSMA) advanced into preclinical and Phase I stages with reported cellular and humoral responses.
TRP2-targeting replicon vaccine (melanoma)
Replicon vaccine expressing the melanoma antigen TRP2 demonstrating therapeutic efficacy in preclinical models and studied in combination with immunomodulatory antibodies.
CMV replicon vaccine (cytomegalovirus)
Two-component replicon vaccine expressing CMV antigens (gB and pp65/IE1 fusion) evaluated in Phase I trials producing neutralizing antibodies and robust CD4+/CD8+ T cell responses.
Influenza replicon vaccines (seasonal and pandemic)
Replicon vaccines expressing influenza hemagglutinin (HA) evaluated in preclinical and clinical contexts, showing protection in multiple species and induction of protective antibody and T cell responses in humans and animals.
CEA-targeting replicon vaccine (colon/gastrointestinal cancer)
Replicon particle vaccine expressing carcinoembryonic antigen (CEA) evaluated in Phase I/II trials to elicit CEA-specific T cell and antibody responses and reduce regulatory T cell frequency.
HER2-targeting replicon vaccine (breast cancer)
Replicon particle vaccine expressing HER2 antigen tested in patients with HER2-expressing tumors to induce HER2-specific memory CD8 T cells and systemic immune responses.
PSMA-targeting replicon vaccine (prostate cancer)
Replicon particle vaccine encoding prostate-specific membrane antigen (PSMA) advanced into preclinical and Phase I stages with reported cellular and humoral responses.
TRP2-targeting replicon vaccine (melanoma)
Replicon vaccine expressing the melanoma antigen TRP2 demonstrating therapeutic efficacy in preclinical models and studied in combination with immunomodulatory antibodies.
CMV replicon vaccine (cytomegalovirus)
Two-component replicon vaccine expressing CMV antigens (gB and pp65/IE1 fusion) evaluated in Phase I trials producing neutralizing antibodies and robust CD4+/CD8+ T cell responses.
Influenza replicon vaccines (seasonal and pandemic)
Replicon vaccines expressing influenza hemagglutinin (HA) evaluated in preclinical and clinical contexts, showing protection in multiple species and induction of protective antibody and T cell responses in humans and animals.
Expertise Areas
- Self-replicating RNA vaccine platform development
- Cancer immunotherapy vaccine development
- Prophylactic infectious disease vaccine development
- Preclinical animal models and challenge studies
Key Technologies
- Self-replicating RNA (replicon) particle vaccines
- Virus-like replicon particles (VRP)
- Dendritic cell-targeting antigen delivery
- VRP-based adjuvant expression